The low translational effectivity of animal fashions to people, and the event of new-age methodologies which are human-cell based mostly, is fuelling a paradigm change throughout the globe. On this views paper, we talk about the present state of analysis, funding, and regulation in these 21st century applied sciences, together with organoids and organ-on-chip in India. Not too long ago, a road-map was drawn by Indian Council for Medical Analysis (ICMR) relating to options to animals in analysis in India and it additionally held a particular session in January 2018 to debate newest developments in new human-relevant mannequin techniques.
We doc the regulatory and analysis panorama on this subject in India. We additionally talk about the challenges current on this subject which embrace lack of coaching and abilities to deal with embryonic or induced pluripotent stem cell (iPSC) strains, funding limitations, lack of home manufacturing of reagents resulting in elevated prices, and lack of infrastructure, comparable to microfabrication amenities. Ultimately, we offer suggestions to allow innovation and software of human-relevant methodologies to develop India as a key participant on this area globally.
Plastic air pollution is without doubt one of the largest environmental issues dealing with the world. Lately, microplastics, polymer particles from 1 µm to five mm, have been getting a lot consideration. The presence of microplastics has already been confirmed in aquatic and marine ecosystems, soil, environment, biota, and others. The natural output from mechanical-biological remedy (MBT) crops was added to the checklist of microplastics sources solely lately. Nevertheless, in keeping with preliminary estimates, it might be the second-largest supply of microplastics.
This text presents an outline of already printed investigations on this microplastics supply and explains the supposed pathway of microplastics within the MBT crops. The principle waste remedy processes that may have an effect on the quantity of microplastics within the natural output have been recognized as shredding, sieving and, to a lesser extent, cardio or anaerobic processing. This mini-review additionally contains strategies used within the scientific literature for microplastics extraction, purification, and identification in organic-rich samples, their benefits and limitations. Specific consideration is paid to the strategies of figuring out the small microplastics, lower than 1 mm, because the strategies for particles 1-5 mm have been extra extensively studied. Moreover, future analysis wants are highlighted.
Comparability of cytotoxicity and smear layer elimination efficacy of triphala (an Indian ayurvedic natural formulation) and 5.25% sodium hypochlorite as root canal irrigants: An in vitro research
Therapeutic potential of crops is an age-old concept that has lately attained renewed curiosity. Contemplating the ineffectiveness, probably dangerous results, and security considerations of generally used artificial irrigants, the natural options for endodontic utilization may show to be advantageous.
The goal of this research was to judge the adequacy of smear layer elimination and cytotoxicity potential of triphala compared to sodium hypochlorite.
The research was performed in two elements: the primary a part of the research was cytotoxicity evaluation studied utilizing Alamar blue assay. L929 mouse fibroblasts have been seeded in 96-well plates at a density of 5000 cells/nicely and handled with completely different concentrations of triphala and NaOCl for a interval of 24 and 48 h. The share of cell viability was then quantified utilizing an Alamar blue assay. The optical density was measured at 570 nm and in contrast with 620 nm, which was thought of as a reference wavelength. The second a part of the research was smear layer evaluation on the coronal, center, and apical third of twenty human premolar enamel utilizing scanning electron microscope.
The Alamar blue reagent cytotoxicity research instructed that triphala confirmed no cytotoxic properties in opposition to the conventional mouse fibroblast cells whereas sodium hypochlorite confirmed a big cytotoxic impact in opposition to the L929 cell strains with the IC50 focus at 1.8%, respectively, after the remedy of 24 h of incubation at 37°C temperature. Triphala was as efficient as sodium hypochlorite in smear layer elimination within the coronal and center third of the basis, however sodium hypochlorite confirmed higher smear layer elimination within the apical third.
Triphala might be thought of as a superior irrigant with good antibacterial efficacy and least cytotoxicity potential in comparison with typical hypochlorite irrigating agent and supply satisfactory clearing of smear layer within the coronal and center third, and additional research are warranted to change the properties of liquid to make it extra cleansable within the apical third of the basis
Peptide-Primarily based Nanomaterials for Tumor Immunotherapy
With the rising understanding of tumor immune circulation mechanisms, tumor immunotherapy together with immune checkpoint blockade has develop into a analysis hotspot, which requires the event of extra correct and extra environment friendly medicine with fewer negative effects.
In step with this requirement, peptides with good biocompatibility, focusing on, and specificity develop into favorable theranostic reagents, and a sequence of promising candidates for tumor immunotherapy based mostly on peptides have been developed. Moreover, the benefits of nanomaterials as drug carriers comparable to larger affinity have been demonstrated, offering prospects of mixture remedy. On this evaluate, we summarize the event of peptide-based nanomaterials in tumor immunotherapy from the 2 elements of functionalization and self-assembly.
Cttnbp2nl ORF Vector (Mouse) (pORF) |
|
ORF042239 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Cttnbp2nl ORF Vector (Mouse) (pORF) |
|
ORF042240 |
ABM |
1.0 ug DNA |
EUR 607.2 |
CTTNBP2NL Protein Vector (Rat) (pPM-C-HA) |
|
PV262384 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Rat) (pPB-C-His) |
|
PV262382 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Rat) (pPB-N-His) |
|
PV262383 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Rat) (pPM-C-His) |
|
PV262385 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Mouse) (pPM-C-HA) |
|
PV168952 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Mouse) (pPM-C-HA) |
|
PV168956 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Mouse) (pPM-C-HA) |
|
PV168960 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Human) (pPM-C-HA) |
|
PV011167 |
ABM |
500 ng |
EUR 394.8 |
CTTNBP2NL Protein Vector (Mouse) (pPB-C-His) |
|
PV168950 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Mouse) (pPB-N-His) |
|
PV168951 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Mouse) (pPM-C-His) |
|
PV168953 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Mouse) (pPB-C-His) |
|
PV168954 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Mouse) (pPB-N-His) |
|
PV168955 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Mouse) (pPM-C-His) |
|
PV168957 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Mouse) (pPB-C-His) |
|
PV168958 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Mouse) (pPB-N-His) |
|
PV168959 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Mouse) (pPM-C-His) |
|
PV168961 |
ABM |
500 ng |
EUR 723.6 |
CTTNBP2NL Protein Vector (Human) (pPB-C-His) |
|
PV011165 |
ABM |
500 ng |
EUR 394.8 |
CTTNBP2NL Protein Vector (Human) (pPB-N-His) |
|
PV011166 |
ABM |
500 ng |
EUR 394.8 |
CTTNBP2NL Protein Vector (Human) (pPM-C-His) |
|
PV011168 |
ABM |
500 ng |
EUR 394.8 |
CTTNBP2NL |
|
CSB-CL865207HU |
Cusabio |
10 μg plasmid + 200μl Glycerol |
Ask for price |
Lenti ORF clone of Cttnbp2nl (mGFP-tagged ORF) - Rat CTTNBP2 N-terminal like (Cttnbp2nl), (10 ug) |
|
RR202426L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF particles, CTTNBP2NL (mGFP-tagged) - Human CTTNBP2 N-terminal like (CTTNBP2NL), 200ul, >10^7 TU/mL |
|
RC203727L2V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, CTTNBP2NL (mGFP-tagged) - Human CTTNBP2 N-terminal like (CTTNBP2NL), 200ul, >10^7 TU/mL |
|
RC203727L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Cttnbp2nl (GFP-tagged ORF) - Rat CTTNBP2 N-terminal like (Cttnbp2nl), 200ul, >10^7 TU/mL |
|
RR202426L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, CTTNBP2NL (Myc-DDK tagged) - Human CTTNBP2 N-terminal like (CTTNBP2NL), 200ul, >10^7 TU/mL |
|
RC203727L1V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, CTTNBP2NL (Myc-DDK tagged) - Human CTTNBP2 N-terminal like (CTTNBP2NL), 200ul, >10^7 TU/mL |
|
RC203727L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF clone of Cttnbp2nl (Myc-DDK-tagged ORF) - Rat CTTNBP2 N-terminal like (Cttnbp2nl), (10 ug) |
|
RR202426L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Cttnbp2nl - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|
TL706262V |
Origene Technologies GmbH |
500 ul each |
Ask for price |
Cttnbp2nl - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|
TL505330V |
Origene Technologies GmbH |
500 ul each |
Ask for price |
CTTNBP2NL - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|
TL305169V |
Origene Technologies GmbH |
500 ul each |
Ask for price |
Lenti ORF particles, Cttnbp2nl (Myc-DDK-tagged ORF) - Rat CTTNBP2 N-terminal like (Cttnbp2nl), 200ul, >10^7 TU/mL |
|
RR202426L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Cttnbp2nl sgRNA CRISPR Lentivector set (Rat) |
|
K6403801 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
CTTNBP2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV662881 |
ABM |
1.0 ug DNA |
EUR 3093.6 |
CTTNBP2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV662885 |
ABM |
1.0 ug DNA |
EUR 3093.6 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) |
|
MBS6007388-02mL |
MyBiosource |
0.2(mL |
EUR 695 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) |
|
MBS6007388-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2975 |
Lenti ORF clone of Cttnbp2nl (mGFP-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 1 |
|
MR217706L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF clone of Cttnbp2nl (mGFP-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 3 |
|
MR216171L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF clone of Cttnbp2nl (mGFP-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 2 |
|
MR209671L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
CTTNBP2NL sgRNA CRISPR Lentivector set (Human) |
|
K0531401 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Cttnbp2nl sgRNA CRISPR Lentivector set (Mouse) |
|
K4656201 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
CTTNBP2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV662886 |
ABM |
1.0 ug DNA |
EUR 3093.6 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (AP) |
|
MBS6289979-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (AP) |
|
MBS6289979-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (PE) |
|
MBS6289989-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (PE) |
|
MBS6289989-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (APC) |
|
MBS6289980-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (APC) |
|
MBS6289980-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (FITC) |
|
MBS6289982-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (FITC) |
|
MBS6289982-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
Lenti ORF clone of Cttnbp2nl (Myc-DDK-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 1 |
|
MR217706L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF clone of Cttnbp2nl (Myc-DDK-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 3 |
|
MR216171L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF clone of Cttnbp2nl (Myc-DDK-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 2 |
|
MR209671L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Cttnbp2nl (untagged ORF) - Rat CTTNBP2 N-terminal like (Cttnbp2nl), (10 ug) |
|
RN202426 |
Origene Technologies GmbH |
10 µg |
Ask for price |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (Biotin) |
|
MBS6289981-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (Biotin) |
|
MBS6289981-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
Cttnbp2nl sgRNA CRISPR Lentivector (Rat) (Target 1) |
|
K6403802 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Cttnbp2nl sgRNA CRISPR Lentivector (Rat) (Target 2) |
|
K6403803 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Cttnbp2nl sgRNA CRISPR Lentivector (Rat) (Target 3) |
|
K6403804 |
ABM |
1.0 ug DNA |
EUR 184.8 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (MaxLight 405) |
|
MBS6289984-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (MaxLight 405) |
|
MBS6289984-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (MaxLight 490) |
|
MBS6289985-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (MaxLight 490) |
|
MBS6289985-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (MaxLight 550) |
|
MBS6289986-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (MaxLight 550) |
|
MBS6289986-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (MaxLight 650) |
|
MBS6289987-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (MaxLight 650) |
|
MBS6289987-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (MaxLight 750) |
|
MBS6289988-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (MaxLight 750) |
|
MBS6289988-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTTNBP2NL sgRNA CRISPR Lentivector (Human) (Target 1) |
|
K0531402 |
ABM |
1.0 ug DNA |
EUR 184.8 |
CTTNBP2NL sgRNA CRISPR Lentivector (Human) (Target 2) |
|
K0531403 |
ABM |
1.0 ug DNA |
EUR 184.8 |
CTTNBP2NL sgRNA CRISPR Lentivector (Human) (Target 3) |
|
K0531404 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Cttnbp2nl sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|
K4656202 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Cttnbp2nl sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|
K4656203 |
ABM |
1.0 ug DNA |
EUR 184.8 |
Cttnbp2nl sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|
K4656204 |
ABM |
1.0 ug DNA |
EUR 184.8 |
CTTNBP2NL cDNA Clone |
|
MBS1266265-001mgPlasmid02mLGlycerolStock |
MyBiosource |
0.01mgPlasmid+0.2mLGlycerol-Stock |
EUR 615 |
CTTNBP2NL cDNA Clone |
|
MBS1266265-5x001mgPlasmid5x02mLGlycerolStock |
MyBiosource |
5x0.01mgPlasmid+5x0.2mLGlycerol-Stock |
EUR 2720 |
Cttnbp2nl (Myc-DDK-tagged ORF) - Rat CTTNBP2 N-terminal like (Cttnbp2nl), (10 ug) |
|
RR202426 |
Origene Technologies GmbH |
10 µg |
Ask for price |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (Azide free) (HRP) |
|
MBS6289983-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTTNBP2NL, NT (CTTNBP2NL, KIAA1433, CTTNBP2 N-terminal-like protein) (Azide free) (HRP) |
|
MBS6289983-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
Lenti ORF particles, Cttnbp2nl (GFP-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 1, 200ul, >10^7 TU/mL |
|
MR217706L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Cttnbp2nl (GFP-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 3, 200ul, >10^7 TU/mL |
|
MR216171L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Cttnbp2nl (GFP-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 2, 200ul, >10^7 TU/mL |
|
MR209671L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Mouse CTTNBP2NL siRNA |
|
20-abx913166 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Human CTTNBP2NL siRNA |
|
20-abx913167 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
CTTNBP2NL siRNA (Mouse) |
|
MBS8231596-15nmol |
MyBiosource |
15nmol |
EUR 405 |
CTTNBP2NL siRNA (Mouse) |
|
MBS8231596-30nmol |
MyBiosource |
30nmol |
EUR 565 |
CTTNBP2NL siRNA (Mouse) |
|
MBS8231596-5x30nmol |
MyBiosource |
5x30nmol |
EUR 2450 |
CTTNBP2NL siRNA (Human) |
|
MBS8211563-15nmol |
MyBiosource |
15nmol |
EUR 405 |
CTTNBP2NL siRNA (Human) |
|
MBS8211563-30nmol |
MyBiosource |
30nmol |
EUR 565 |
CTTNBP2NL siRNA (Human) |
|
MBS8211563-5x30nmol |
MyBiosource |
5x30nmol |
EUR 2450 |
Lenti ORF particles, Cttnbp2nl (Myc-DDK-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 1, 200ul, >10^7 TU/mL |
|
MR217706L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Cttnbp2nl (Myc-DDK-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 3, 200ul, >10^7 TU/mL |
|
MR216171L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Cttnbp2nl (Myc-DDK-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 2, 200ul, >10^7 TU/mL |
|
MR209671L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
CTTNBP2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV662882 |
ABM |
1.0 ug DNA |
EUR 3093.6 |
anti- CTTNBP2NL antibody |
|
FNab02069 |
FN Test |
100µg |
EUR 658.5 |
|
|
|
Description: Antibody raised against CTTNBP2NL |
Cttnbp2nl - Rat, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|
TR706262 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
Cttnbp2nl (untagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 1, (10ug) |
|
MC200168 |
Origene Technologies GmbH |
10 µg |
Ask for price |
CTTNBP2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV662883 |
ABM |
1.0 ug DNA |
EUR 3163.2 |
CTTNBP2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV662884 |
ABM |
1.0 ug DNA |
EUR 3163.2 |
CTTNBP2NL cloning plasmid |
|
CSB-CL865207HU-10ug |
Cusabio |
10ug |
EUR 776.4 |
|
|
|
Description: A cloning plasmid for the CTTNBP2NL gene. |
Cttnbp2nl - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|
TR505330 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
CTTNBP2NL - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|
TR305169 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
Cttnbp2nl (GFP-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl) transcript variant 1, (10ug) |
|
MG217706 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Cttnbp2nl (GFP-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl) transcript variant 3, (10ug) |
|
MG216171 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Cttnbp2nl (Myc-DDK-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 1 |
|
MR217706 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Cttnbp2nl (Myc-DDK-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 3 |
|
MR216171 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Cttnbp2nl (Myc-DDK-tagged) - Mouse CTTNBP2 N-terminal like (Cttnbp2nl), transcript variant 2 |
|
MR209671 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Cttnbp2 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL708241 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
CTTNBP2NL (NM_018704) Human Recombinant Protein |
|
E45H40196M5 |
EnoGene |
20 ug |
EUR 785.42 |
Cttnbp2nl (NM_001163332) Mouse Recombinant Protein |
|
E45M45408M5 |
EnoGene |
20 ug |
EUR 1924.54 |
CTTNBP2NL (NM_018704) Human Recombinant Protein |
|
PROTQ9P2B4 |
BosterBio |
20ug |
EUR 1249 |
|
Description: Recombinant protein of human CTTNBP2 N-terminal like (CTTNBP2NL) |
CTTNBP2NL Antibody (N-term) |
|
E45R15642G-1 |
EnoGene |
100 ul |
EUR 395 |
CTTNBP2NL Antibody (N-term) |
|
E45R15642G-4 |
EnoGene |
50 ul |
EUR 295 |
CTTNBP2NL Antibody (N-term) |
|
MBS9209611-008mL |
MyBiosource |
0.08mL |
EUR 210 |
CTTNBP2NL Antibody (N-term) |
|
MBS9209611-04mL |
MyBiosource |
0.4mL |
EUR 430 |
CTTNBP2NL Antibody (N-term) |
|
MBS9209611-5x04mL |
MyBiosource |
5x0.4mL |
EUR 1910 |
Cttnbp2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL502777 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
CTTNBP2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL305170 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
Cttnbp2nl sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|
K6403805 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
Mouse CTTNBP2NL shRNA Plasmid |
|
20-abx979012 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Human CTTNBP2NL shRNA Plasmid |
|
20-abx961012 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Human CTTNBP2NL Protein Lysate |
|
MBS8410104-002mg |
MyBiosource |
0.02mg |
EUR 365 |
Human CTTNBP2NL Protein Lysate |
|
MBS8410104-5x002mg |
MyBiosource |
5x0.02mg |
EUR 1410 |
CTTNBP2NL sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|
K0531405 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
Cttnbp2nl sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|
K4656205 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
CTTNBP2NL (N-term) Rabbit pAb |
|
E2618445 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
CTTNBP2NL (N-Term) Rabbit pAb |
|
MBS8556745-01mL |
MyBiosource |
0.1mL |
EUR 305 |
CTTNBP2NL (N-Term) Rabbit pAb |
|
MBS8556745-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
CTTNBP2NL (N-Term) Rabbit pAb |
|
MBS8556745-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
CTTNBP2NL (N-Term) Rabbit pAb |
|
MBS8556745-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
CTTNBP2NL (N-Term) Rabbit pAb |
|
MBS8556745-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
CTTNBP2NL Recombinant Protein (Rat) |
|
RP196784 |
ABM |
100 ug |
Ask for price |
Lenti ORF clone of Human CTTNBP2 N-terminal like (CTTNBP2NL), mGFP tagged |
|
RC203727L2 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF clone of Human CTTNBP2 N-terminal like (CTTNBP2NL), mGFP tagged |
|
RC203727L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
CTTNBP2NL (NM_018704) Human Over-expression Lysate |
|
E45H10858-2 |
EnoGene |
each |
EUR 395 |
CTTNBP2NL (NM_018704) Human Over-expression Lysate |
|
LS055917 |
BosterBio |
100ug |
EUR 628 |
|
|
|
Description: Transient overexpression lysate of CTTNBP2 N-terminal like (CTTNBP2NL) |
Cttnbp2nl sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|
K6403806 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Cttnbp2nl sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|
K6403807 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Cttnbp2nl sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|
K6403808 |
ABM |
1.0 ug DNA |
EUR 200.4 |
Recombinant Human CTTNBP2NL Protein |
|
E30P66526A |
EnoGene |
50 ug |
EUR 295 |
CTTNBP2NL Recombinant Protein (Mouse) |
|
RP126710 |
ABM |
100 ug |
Ask for price |
CTTNBP2NL Recombinant Protein (Mouse) |
|
RP126713 |
ABM |
100 ug |
Ask for price |
CTTNBP2NL Recombinant Protein (Mouse) |
|
RP126716 |
ABM |
100 ug |
Ask for price |
CTTNBP2NL Recombinant Protein (Human) |
|
RP008374 |
ABM |
100 ug |
Ask for price |
Moreover, new strategies for peptide screening, particularly machine-learning-related methods, can be a subject we have been interested by, as this types the idea for the development of peptide-based platforms. Peptides present broad prospects for tumor immunotherapy and we hope that this abstract can present perception into potential avenues for future exploration.